Non-manageable graft versus host disease.
Active graft-versus-host disease.
Active graft-versus-host disease.
Participants must have cGVHD (as defined by the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease)
Current or history of graft versus host disease
Active chronic graft versus host disease requiring immunosuppressive treatment.
Patients with >= grade  acute graft-versus-host disease are excluded from the study
Patients with moderate or severe chronic graft-versus host requiring more than  mg of oral prednisone or equivalent therapy are excluded from the study
there are no signs or symptoms of graft versus host disease, other than Grade  skin involvement.
GRAFT CRITERIA:
No prior therapy with mTOR inhibitors except for rapalog treatment as part of graft-versus-host (GVH) prophylaxis or treatment
Graft must be a CD+ T-cell replete PBSC graft or non-manipulated BM graft.
Active acute graft versus (vs.) host disease >= grade  or active extensive chronic graft versus host disease (GVHD)
Presence of chronic graft versus host disease (cGVHD) in an organ other than lung
Active graft-versus-host disease.
Active hepatic graft-versus-host disease
Active graft versus-host disease and must not be on immunosuppression
Participants who have received immunosuppressive therapy for graft versus host disease within  weeks prior to randomization
Any level of acute graft versus host disease
GRAFT CRITERIA:
DONOR: Donors will be selected to minimize HLA mismatch in the host-versus-graft direction
Active acute graft-versus-host disease of any grade or chronic graft-versus-host disease of Grade  or higher
Signs of or symptoms of active graft versus host disease
Patients with symptomatic oral chronic graft-versus-host disease (sensitivity score >= )
Graft-versus-host disease criteria:
Active graft-versus-host disease.
Active graft-versus-host disease.
Active acute grade III-IV graft-versus-host disease
Ongoing graft-versus-host disease
Prior use of fludarabine, as this agent has been associated with higher subsequent rates of graft versus host disease
Active graft?versus?host disease requiring systemic treatment
Subjects who have clinically significant graft versus host disease requiring treatment and /or have >grade  persistent non hematological toxicity related to transplant
Participants who received prior allogenic transplant must have had no active graft-versus-host disease.
Active graft versus host disease.
Presence of uncontrolled graft-versus-host disease
Evidence of graft versus host disease > grade II
Evidence of chronic or acute graft versus host disease or on-going treatment for graft versus host disease from prior allogeneic stem cell transplantation
Current immunosuppressive treatment for graft versus host disease
Active graft versus host disease
No signs or symptoms of graft versus host disease other than Grade  skin involvement
Has clinically significant graft-versus-host disease requiring treatment
Ongoing graft-versus (vs)-host disease
Evidence of uncontrolled graft-versus-host disease
Receiving systemic therapy for chronic graft-versus-host disease (topical therapy is allowed)
Post allo patients must not have active graft versus-host disease and be off all immune suppression (other than steroids, as above)
Any evidence of cGVHD or late acute graft versus host disease (aGVHD) between enrollment and first dose of obinutuzumab
Active systemic treatment for graft versus host disease.
HSCT recipients with active and/or chronic graft versus host disease
Subject has received a prior HCT and has residual Chronic Graft-versus-host Disease (cGVHD)
Hematopoietic stem cell transplantation (HSCT) within  days of screening, or receipt of immunosuppressive therapy for graft-versus-host disease treatment or prophylaxis within  days of first protocol therapy, or active graft-versus-host-disease
Active graft-versus-host disease.
